VIDEO: DUR-928 well tolerated at three doses for treatment of NASH

In this exclusive video, Eric Lawitz, MD, from the Texas Liver Institute, University of Texas Health, San Antonio, spoke about DUR-928, a daily oral treatment for nonalcoholic steatohepatitis.DUR-928 was well tolerated at 50 mg, 150 mg and 300 mg, with no serious adverse events reported, according to Lawitz. At 4 weeks, the median liver fat reduction was –18% at 50 mg, –19% at 150 mg and –23 at 300 mg as measured by MRI-PDFF.Lawitz said that DUR-928 showed overall improvement in multiple markers such as liver enzymes, liver imaging and serum lipid profiles.Read More